Blepharospasm Patient Survey for Patients With Blepharospasm

Learn more about:
Related Clinical Trial
Data Analysis of Protocol 04-N-0188: Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm Mexiletine for the Treatment of Focal Dystonia A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm An RCT of a Patient-initiated Treatment Service for BEB and HFS Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Photic Blink Reflex in People With Blepharospasm and Increased Blinking IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm Blepharospasm Short Interval Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm Brain Changes in Blepharospasm Blepharospasm Patient Survey for Patients With Blepharospasm A Mechanical Device for Blepharospasm Blepharospasm Tools Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

Brief Title

Blepharospasm Patient Survey for Patients With Blepharospasm

Official Title

Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm

Brief Summary

      The purpose of this survey is to collect detailed information on patients treated for
      blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including
      how often they are treated with botulinum toxin, how long their treatment lasts, how
      satisfied they are with their treatment, and if there is any improvement in their symptoms
      with the treatment.
    

Detailed Description

      This study is open to males and females > 18 years and < 81 years with a clinical diagnosis
      of blepharospasm.
    


Study Type

Observational


Primary Outcome

Botulinum Toxin Treatment Information


Condition

Blepharospasm

Intervention

No intervention- only one time survey

Study Arms / Comparison Groups

 Blepharospasm Survey Group
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

124

Start Date

September 2012

Completion Date

April 2013

Primary Completion Date

April 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Male or female subject aged > 18 years and < 81 years

          -  Documented clinical diagnosis of blepharospasm

          -  Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA

        Exclusion Criteria:

          -  Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles
      

Gender

All

Ages

18 Years - 81 Years

Accepts Healthy Volunteers

No

Contacts

Micki Seoane, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01686061

Organization ID

MUS6020100920


Responsible Party

Sponsor

Study Sponsor

Merz North America, Inc.


Study Sponsor

Micki Seoane, Study Director, Merz Pharmaceutical, LLC


Verification Date

April 2014